Browsing by Author "Popovic, Jovan (56715268600)"
Now showing 1 - 7 of 7
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Arteriovenous fistula aneurysm in patients on regular hemodialysis: Prevalence and risk factors(2013) ;Jankovic, Aleksandar (55908877300) ;Donfrid, Branislav (57199525699) ;Adam, Jelena (56375569200) ;Ilic, Marjan (55408459700) ;Djuric, Zivka (20733933700) ;Damjanovic, Tatjana (6603050029) ;Popovic, Jovan (56715268600) ;Popovic, Gordana (57198029593) ;Radojicic, Zoran (6507427734)Dimkovic, Nada (6603958094)Background/Aims: Compared to all other complications, literature data about vascular access aneurysm (VAA) are the scarcest. The aim of this cross-sectional study was to evaluate the prevalence of arteriovenous fistula (AVF) aneurysms and to confirm the risk factors for their appearance. Methods: The presence, number and morphological characteristics of AVF aneurysms were confirmed, and according to the score of AVF aneurysm (the sum of the length and width in cm), patients were classified into group 1 (score ≤12) and group 2 (score >12). Analysis included the last data from the medical records including vascular calcifications score. Results: Out of 181 patients, 150 with native fistula were included in this study. Aneurysmatic changes were detected in 90 (60%) patients, and the majority had two or more aneurysms. VAA were more frequent in patients with adult polycystic kidney disease (ADPKD) than in other diagnostic categories. By using forward stepwise logistic regression, we confirmed that patients on high-flux hemodialysis (HD) had 5.3-fold higher risk, and patients with diabetes mellitus had 5.8-fold less risk for developing AVF aneurysm. While vascular calcification score did not influence the incidence of VAA, higher PWV had significant negative influence on formation of AVF aneurysm (OR 1.25, 95% CI 1.003-1.56, p = 0.047). By ROC curve analysis, it was determined that patients who were longer than 5.7 years on HD had greater risk for developing VAA (area = 0.741, p = 0.000). Conclusion: This single-center study confirmed the very high prevalence of VAA (60%). Aneurysms were more frequent in patients with ADPKD and in those who had longer dialysis vintage on high-flux membranes with higher blood flow rate. © 2013 S. Karger AG, Basel. - Some of the metrics are blocked by yourconsent settings
Publication Calcification in arteriovenous fistula blood vessels may predict arteriovenous fistula failure: a 5-year follow-up study(2017) ;Jankovic, Aleksandar (55908877300) ;Damjanovic, Tatjana (6603050029) ;Djuric, Zivka (20733933700) ;Marinkovic, Jelena (7004611210) ;Schlieper, Georg (6602109014) ;Djuric, Petar (56979881000) ;Dragovic, Jelena Tosic (57192300480) ;Bulatovic, Ana (35736942600) ;Mitrovic, Milos (56979859800) ;Popovic, Jovan (56715268600) ;Floege, Jürgen (55961563700)Dimkovic, Nada (6603958094)Purpose: Arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis. The impact of vascular calcification process on AVF survival remains unclear and results of several studies about this issue are controversial. In the light of the new knowledge about the different susceptibility for calcification process in different blood vessels, the aim of our study was to analyze whether the calcification of AVF-blood vessels may have an impact on AVF longevity. Methods: The study included 90 patients, 49 males and 41 females, all of them Caucasians, with a mean age 62 ± 11 years, on regular hemodialysis for more than 1 year with patent primary AVFs. Vascular calcification in AVF-blood vessels or in the anastomotic region was detected using X-ray examination. Results: Calcification in AVF-blood vessels was found in 62% of patients. Binary logistic regression analysis demonstrated that male gender, presence of diabetes mellitus and longer duration of AVF before calcification determination were associated with calcification of AVF-blood vessels. Using a Cox proportional hazard model adjusted for these standardized predicted values revealed that patients with present AVF-blood vessels calcification had increased risk to develop AVF failure with a hazard rate of 3.42 (95% confidence interval 1.00–11.67; P = 0.049). Conclusions: Calcifications of AVF-blood vessels are found frequently among dialysis patients and may jeopardize the survival of native AVF. We suggested the local X-ray as simple and valid method for detection of patients that are at risk for AVFs failure which should be monitored more closely. © 2017, Springer Science+Business Media Dordrecht. - Some of the metrics are blocked by yourconsent settings
Publication Impact of angiotensin-converting enzyme and matrix metalloproteinase-3 gene polymorphisms on risk for developing vascular access failure in hemodialysis patients - A pilot study(2019) ;Jankovic, Aleksandar (55908877300) ;Tosic, Jelena (57225255338) ;Buzadzic, Ivana (38661047900) ;Djuric, Petar (56979881000) ;Bulatovic, Ana (35736942600) ;Marković, Dragana (24426339600) ;Popovic, Jovan (56715268600)Dimkovic, Nada (6603958094)For adequate hemodialysis, functional vascular access is obligatory. Neointimal hyperplasia (NIH) has a central role in stenosis and thrombosis development, which represent the most frequent causes of vascular access failure. Polymorphism of different genes that have a significant role in endothelial function may have an impact on NIH development. Therefore, the aim of our study is to determine the effect of angiotensin-converting enzyme (ACE) I/D and matrix metalloproteinase-3 (MMP3) 5A/6A polymorphism on risk for developing vascular access failure in hemodialysis patients. The study included 200 patients on regular hemodialysis at Nephrology Department, University Medical Center Zvezdara. Retrospective analysis included a collection of general and vascular access data from medical records. Genetic analysis was performed by using polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP). Patients were divided into two groups: Group 1 - patients who have never experienced vascular access failure and Group 2 - patients who have at least one spontaneous vascular access failure. There was no difference in age, gender, hemodialysis vintage, main diagnosis, presence of hypertension, and diabetes mellitus between the two groups. There were no statistically significant differences in the frequencies of ACE and MMP3 genotypes between the two groups. Without statistical significance, it was found that homozygotes for I allele had two times higher risk for developing vascular access failure than homozygotes for D allele (OR 2.00; 95%CI: 0.727-5.503; P = 0.180). In addition, patients with 5A allele have 1.7 times higher risk for developing vascular access failure compared with patients without this allele (OR 1.745; 95% CI: 0.868-3.507; P = 0.118). Patients with vascular access failure do not have different genotype distribution regarding ACE gene and MMP3 gene polymorphism as compared with patients without vascular access failure. Still, homozygotes for I allele and homozygotes for 5A allele have higher risk for developing vascular access failure compared with other patients. © 2019 Wolters Kluwer Medknow Publications. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Impact of Vascular Calcifications on Arteriovenous Fistula Survival in Hemodialysis Patients: A Five-Year Follow-Up(2015) ;Jankovic, Aleksandar (55908877300) ;Damjanovic, Tatjana (6603050029) ;Djuric, Zivka (20733933700) ;Marinkovic, Jelena (7004611210) ;Schlieper, Georg (6602109014) ;Tosic-Dragovic, Jelena (57192300480) ;Djuric, Petar (56979881000) ;Popovic, Jovan (56715268600) ;Floege, Juergen (55961563700)DImkovic, Nada (6603958094)Background/Aims: Vascular calcifications are frequently found among dialysis patients, and the calcification process may influence the patient's outcome. The aim of the present study was to determine the role that vascular calcifications may have on autologous arteriovenous fistula (AVF) survival. Methods: This study included 90 patients (49 males, mean age 62 ± 11) with a native AVF treated by chronic hemodialysis (HD) for more than one year. The overall vascular calcification scores ranged from 0-11 (Adragao score + vascular access calcification score); patients were categorized into mild (score 0-3; n = 36), moderate (score 4-7; n = 24) and severe (score 8-11; n = 30) calcification groups. AVF survival was then followed for 5 years after calcification measurement or until the patient's death/transplantation. Results: Patients with more pronounced vascular calcifications were more frequently diabetic and male. Multiple linear regression analysis showed a significant relationship between calcification score and male gender, diabetes mellitus, previous duration of AVF, low dialysis flow rate and intact parathormone (iPTH) values. After multivariate adjustment for basal differences, Cox proportional analysis revealed a graded impact of calcification scores on AVF failure: moderate scores (were associated with a hazard rate (HR) of 3.82 (95% confidence interval (CI) 1.10-13.23) and severe scores with an HR of 4.65 (CI 0.97-22.38). Conclusion: Vascular calcifications are associated with worse survival of native arteriovenous hemodialysis fistulas. © 20152015 S. Karger AG, Basel. Copyright: All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Impact of Vascular Calcifications on Arteriovenous Fistula Survival in Hemodialysis Patients: A Five-Year Follow-Up(2015) ;Jankovic, Aleksandar (55908877300) ;Damjanovic, Tatjana (6603050029) ;Djuric, Zivka (20733933700) ;Marinkovic, Jelena (7004611210) ;Schlieper, Georg (6602109014) ;Tosic-Dragovic, Jelena (57192300480) ;Djuric, Petar (56979881000) ;Popovic, Jovan (56715268600) ;Floege, Juergen (55961563700)DImkovic, Nada (6603958094)Background/Aims: Vascular calcifications are frequently found among dialysis patients, and the calcification process may influence the patient's outcome. The aim of the present study was to determine the role that vascular calcifications may have on autologous arteriovenous fistula (AVF) survival. Methods: This study included 90 patients (49 males, mean age 62 ± 11) with a native AVF treated by chronic hemodialysis (HD) for more than one year. The overall vascular calcification scores ranged from 0-11 (Adragao score + vascular access calcification score); patients were categorized into mild (score 0-3; n = 36), moderate (score 4-7; n = 24) and severe (score 8-11; n = 30) calcification groups. AVF survival was then followed for 5 years after calcification measurement or until the patient's death/transplantation. Results: Patients with more pronounced vascular calcifications were more frequently diabetic and male. Multiple linear regression analysis showed a significant relationship between calcification score and male gender, diabetes mellitus, previous duration of AVF, low dialysis flow rate and intact parathormone (iPTH) values. After multivariate adjustment for basal differences, Cox proportional analysis revealed a graded impact of calcification scores on AVF failure: moderate scores (were associated with a hazard rate (HR) of 3.82 (95% confidence interval (CI) 1.10-13.23) and severe scores with an HR of 4.65 (CI 0.97-22.38). Conclusion: Vascular calcifications are associated with worse survival of native arteriovenous hemodialysis fistulas. © 20152015 S. Karger AG, Basel. Copyright: All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Mycophenolate mofetil in high-risk patients with primary glomerulonephritis: Results of a 1-year prospective study(2009) ;Dimkovic, Nada (6603958094) ;Jovanovic, Dragan (17734929100) ;Kovacevic, Zoran (7006680110) ;Rabrenovic, Violeta (6506693321) ;Nesic, Vidosava (6701399962) ;Savin, Marina (18936901400) ;Mitic, Branka (6603935414) ;Ratkovic, Marina (6603579593) ;Curic, Slobodan (7003830295) ;Mitic, Igor (6602508601) ;Pljesa, Steva (6603281733) ;Perunicic-Pekovic, Gordana (7801435301) ;Marinkovic, Jelena (7004611210) ;Popovic, Jovan (56715268600)Vujic, Danica (55406378700)Background/Aims: Glucocorticoids and classic immunosuppressive drugs can improve disease activity in primary glomerulonephritis (GN). However, these drugs have serious toxicity and patients frequently experience inadequate response or relapse, so there is a need for alternative agents. This multicenter uncontrolled study analyzed the efficacy and safety of mycophenolate mofetil (MMF) in high-risk patients with primary GN. Methods: A total of 51 patients with biopsy-proven membranous (n = 12), membranoproliferative (n = 15), mesangioproliferative (n = 10), focal segmental glomerulosclerosis (n = 13) and minimal change disease (n = 1) received MMF with low-dose corticosteroids for 1 year. The primary outcome included the number of patients with complete/partial remission. Results: Proteinuria significantly decreased, from its median value of 4.9 g/day (IQR 2.9-8.4) to 1.28 g/day (IQR 0.5-2.9), p < 0.001. The urine protein/creatinine ratio significantly improved, from a median of 3.72 (IQR 2.13-6.48) to 0.84 (IQR 0.42-2.01), p < 0.001. The mean area under the curve for proteinuria significantly decreased, from 4.99 ± 3.46 to 2.16 ± 2.46, between the first (visits 1-2) and last (vists 4-5) treatment periods (p < 0.001). The change was similar for every type of GN, without difference between groups. eGFR slightly increased (62.1 ± 31.8 to 65.3 ± 31.8 ml/min, p = n.s.) and ESR, total proteins, albumins, total- and HDL-cholesterol parameters improved significantly. Systolic, diastolic and mean blood pressure decreased (p < 0.02 for systolic blood pressure). The age of patients was the only independent predictor of complete or partial remission. Conclusion: MMF proved to be efficient in 70% of high-risk patients with primary GN, who reached either complete or partial remission without safety concern after 12 months of treatment. Favorable effects of MMF therapy have to be confirmed in the long term and particularly after discontinuation of the drug. © 2009 S. Karger AG, Basel. - Some of the metrics are blocked by yourconsent settings
Publication Survival benefit of hemodiafiltration compared with prolonged high-flux hemodialysis(2016) ;Djuric, Petar S. (56979881000) ;Jankovic, Aleksandar (55908877300) ;Popovic, Jovan (56715268600) ;Dragovic, Jelena Tosic (57192300480) ;Bulatovic, Ana (35736942600) ;Djuric, Živka (20733933700) ;Mitrovic, Milos (56979859800)Dimkovic, Nada (6603958094)Introduction. Patients on dialysis have a high rate of death, mainly of cardiovascular cause. Nephrologists are actively looking for ways to improve patients’ outcomes, and alternative dialysis strategies, such as long conventional hemodialysis and hemodiafiltration, are currently being investigated. The aim of this study was to compare anemia, nutrition, inflammation, mineral metabolism, and 3-year survival rates between patients treated with hemodiafiltration and prolonged high-flux hemodialysis (HFH). Materials and Methods. A total of 58 dialysis patients were divided into 2 groups to undergo hemodiafiltration 3 times weekly, 12 hours in total per week, or prolonged duration of HFH (≥ 15 h/w). One-year biochemical parameters were collected retrospectively, together with 36 months patients’ survival (prospectively). Results. Patients in the HFH group had longer dialysis vintage; significantly higher levels of hemoglobin (despite less frequent use of erythropoietin-stimulating agents), serum albumin, serum calcium, and serum bicarbonate; and a lower intact parathyroid hormone level. Survival rates were comparable between the two groups. The Cox proportional hazard model showed that patients treated with longer HFH had a 32% relative risk reduction of mortality compared to patients treated with hemodiafiltration, but without statistical significance (hazard ratio, 0.68; 95% confidence interval, 0.21 to 2.20; adjusted for diabetes mellitus). Conclusions. Longer duration of hemodialysis with high-flux membranes had beneficial effects on anemia indexes, mineral metabolism, nutrition parameters, and acidosis in comparison with hemodiafiltration. However, hemodiafiltration did not offer a 36-months survival benefit over prolonged HFH. © 2016, Iranian Society of Nephrology. All rights reserved.
